Back to top
more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$46.75 USD

46.75
1,152,445

+0.47 (1.02%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $46.78 +0.03 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wall Street Analysts Think Corcept (CORT) Could Surge 41.31%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Alnylam Pharmaceuticals (ALNY) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.

Here's Why Momentum in Corcept (CORT) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?

by Zacks Equity Research

Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Do Options Traders Know Something About Corcept (CORT) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.

Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report?

by Zacks Equity Research

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept Shares Rise More Than 45% in Six Months: Here's Why

by Zacks Equity Research

CORT's Cushing's syndrome drug, Korlym, has been performing well. The NDA for lead candidate, relacorilant, in Cushing's syndrome will be filed shortly.

Corcept (CORT) Down 4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept (CORT) Upgraded to Buy: Here's Why

by Zacks Equity Research

Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JSML

Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JSML

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia

by Zacks Equity Research

Corcept, Amneal, Bioventus, Foghorn and Akebia have been highlighted in this Industry Outlook article.

Wall Street Analysts Believe Corcept (CORT) Could Rally 70.58%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 70.6% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Kinjel Shah headshot

5 Small Drug Stocks to Buy as Innovation Reaches Peak

by Kinjel Shah

Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's What Could Help Corcept (CORT) Maintain Its Recent Price Strength

by Zacks Equity Research

Corcept (CORT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Can Corcept (CORT) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research

Corcept (CORT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice

by Zacks Equity Research

Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts See a 37.6% Upside in Corcept (CORT): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 37.6% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Corcept (CORT) beats on both earnings and sales in the second quarter of 2024. The company increases revenue guidance for 2024.

Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Corcept (CORT) delivered earnings and revenue surprises of 39.13% and 6.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View

by Zacks Equity Research

Bristol-Myers (BMY) posts impressive second-quarter results, with both earnings and sales beating their respective estimates. The company also raises its annual earnings guidance.